Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term

Qiagen (QGEN), a leading provider of nucleic acid technologies and molecular diagnostics, is identified as a top growth stock, holding a Zacks #2 (Buy) Rank and an 'A' VGM Score, including an 'A' Growth Style Score. This strong rating is underpinned by a forecasted 7.8% year-over-year earnings growth for the current fiscal year, bolstered by five recent analyst upgrades for fiscal 2025 estimates, which raised the consensus to $2.35 per share, and an average earnings surprise of +4.9%.

Analysis

Qiagen (QGEN) presents a strong profile for growth-focused investors, according to the provided analyst report. The company, a key provider of molecular diagnostics and nucleic acid technologies, holds a Zacks #2 (Buy) Rank, which is further supported by an 'A' rating for both its overall VGM (Value, Growth, Momentum) and its specific Growth Style Score. This positive outlook is quantitatively supported by a forecast for 7.8% year-over-year earnings growth in the current fiscal year. Analyst sentiment appears to be improving, as evidenced by five upward earnings estimate revisions for fiscal 2025 within the last 60 days, which has elevated the consensus estimate to $2.35 per share. Furthermore, the company has a demonstrated history of exceeding expectations, boasting an average positive earnings surprise of 4.9%. These combined factors—a strong proprietary rating, positive estimate revisions, and a record of earnings beats—position QGEN as a noteworthy stock based on the metrics highlighted.

Key Decisions for Investors

• Given the Zacks #2 (Buy) Rank and 'A' Growth Score, investors with a growth-oriented mandate should consider QGEN as a potential addition to their portfolios.
• The trend of positive earnings estimate revisions for fiscal 2025 and a history of beating forecasts by an average of 4.9% suggest fundamental momentum; investors should monitor upcoming earnings releases for continuation of this outperformance.
• While the Zacks Rank is designed for 30-day performance, the report's framing of QGEN as a 'long-term' opportunity suggests it could be evaluated for both tactical and strategic allocations.